COMMON STOCK PURCHASE WARRANT ONCBIOMUNE PHARMACEUTICALS, INC.Common Stock Purchase Warrant • June 11th, 2020 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _________, an or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 5, 2020 (the “Initial Exercise Date”) and on or prior to the close of business on September 5, 2025, (the “Termination Date”, provided, however, that if such date is not a Trading Day, the Termination Date shall be the immediately following Trading Day (as defined below)) but not thereafter, to subscribe for and purchase from ONCBIOMUNE PHARMACEUTICALS, INC., a Nevada corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Consulting AgreementConsulting Agreement • June 11th, 2020 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • Colorado
This consulting agreement (the “Agreement”), effective 5th day of June, 2020 (“Effective Date”) by and between Andrew Kucharchuk (“Consultant”), an individual whose address is 549 Millgate Place, Baton Rouge, LA 70808 and OncBioMune Pharmaceuticals, Inc., a Nevada corporation with its principal office located at 8000 Innovation Park Dr., Baton Rouge, LA 70820 together with its affiliates and subsidiaries (“OncBioMune” or the “Company”).
COMMON STOCK PURCHASE WARRANT ONCBIOMUNE PHARMACEUTICALS, inc.Common Stock Purchase Warrant • June 11th, 2020 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • Nevada
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, Doug Mergenthaler (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time after the Issue Date and on or after the filing of an amendment to the Company’s Articles of Incorporation to increase the number of shares of the Company’s Common Stock that the Company is authorized to issue with the Secretary of State of the State of Nevada (the “Initial Exercise Date”) and on or prior to the close of business on the Termination Date (as defined below) but not thereafter, to subscribe for and purchase from OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), of up to 656,674,588 shares (subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”). This Warrant is being issued in connection with the Asset Purchase Agreement, dated May 12,
EXCHANGE AGREEMENTExchange Agreement • June 11th, 2020 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
THIS EXCHANGE AGREEMENT (the “Agreement”) is made as of the 5th day of June 2020, by and between, OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and such persons listed on Schedule I who have executed a signature page to this Agreement (each, an “Investor”).
EXCHANGE AGREEMENTExchange Agreement • June 11th, 2020 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
THIS EXCHANGE AGREEMENT (the “Agreement”) is made as of the 5th day of June 2020, by and between, OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and such persons listed on Schedule I who have executed a signature page to this Agreement (each, an “Investor”).
EXCHANGE AGREEMENTExchange Agreement • June 11th, 2020 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
THIS EXCHANGE AGREEMENT (the “Agreement”) is made as of the 5th day of June 2020, by and between, OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and Jonathan F. Head, Ph.D., a natural person residing in Louisiana (the “Holder”).
SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMSSeparation Agreement • June 11th, 2020 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • Louisiana
This Separation Agreement and General Release of Claims (“Agreement”) is entered into by Andrew Kucharchuk (hereinafter referred to as “you” or “your”) and OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”). In consideration of the mutual promises set forth below, the parties agree as follows:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 11th, 2020 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is effective as of the 5th day of June 2020 (the “Closing Date”), by and between, OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each investor identified on the signature pages to this Agreement (each, an “Investor”).
